Doping control analysis of insulin and its analogues in equine plasma by liquid chromatography-tandem mass spectrometry.
Insulin administration can increase muscle glycogen by utilising hyperinsulinaemic clamps prior to sports events or during the recovery phases, and increase muscle size by its chalonic action to inhibit protein breakdown. In order to control insulin abuse in equine sports, a method to detect effectively the use of insulins in horses would be required. Besides the readily available human insulin and its synthetic analogues, structurally similar insulins from other species can also be used as doping agents. This study describes a method for the simultaneous detection of bovine, porcine and human insulins, as well as the synthetic analogues Humalog (Lilly) and Novolog (Novo Nordisk) in equine plasma. Insulins were isolated from equine plasma by immunoaffinity purification, followed by centrifugal filtration, and analysed by nano-liquid chromatography-tandem mass spectrometry (LC/MS/MS). Insulin and analogues were detected and confirmed by comparing their retention times and major product ions. All five insulins (human insulin, Humalog, Novolog, bovine insulin and porcine insulin), which are exogenous in the horse, could be detected and confirmed at 0.05ng/mL. This method was successful in confirming the presence of human insulin in plasma collected from horses up to 4h after having been administered a single low dose of recombinant human insulin (Humulin R, Eli Lilly). To our knowledge, this is the first identification of exogenous insulin from post-administration horse plasma samples.
Ho
Emmie N M
EN
Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T., Hong Kong, China. emmie.nm.ho@hkjc.org.hk
Wan
Terence S M
TS
Wong
April S Y
AS
Lam
Kenneth K H
KK
Stewart
Brian D
BD
D000818:Animals; D002417:Cattle; D002853:Chromatography, Liquid / Q000379:methods*; D004300:Doping in Sports / Q000517:prevention & control*; D006736:Horses / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000031:analogs & derivatives / Q000097:blood* / Q000302:isolation & purification; D061268:Insulin Lispro; D013552:Swine / Q000097:blood*; D053719:Tandem Mass Spectrometry / Q000379:methods*
D007328:Insulin; D061268:Insulin Lispro